Intellect's early-stage anti-Tau vaccine for Alzheimer's could be first prophylactic
This article was originally published in Scrip
Executive Summary
The tiny company whose technology underpins the development of the experimental anti-beta-amyloid antibodies being developed as an Alzheimer's prophylactic by Janssen, Elan, and Pfizer is looking to leapfrog that approach and develop a second line of attack for Alzheimer's disease therapeutics.